Global Pneumonia Testing Market

The Pneumonia Testing Market size was valued at USD 2.11 Bn. in 2023 and the total Pneumonia Treatment revenue is expected to grow at a CAGR of 7.6% from 2024 to 2030, reaching nearly USD 3.5 Bn. in 2030.

Pneumonia Testing Market Overview:

The Pneumonia is an inflammatory condition of the lung primarily affecting the small air sacs known as alveoli. Pneumonia is usually caused by infection with viruses or bacteria, and less commonly by other microorganisms. Identifying the responsible pathogen is difficult. Diagnosis is often based on symptoms and physical examination.
Demand for pneumonia testing is rising owing to the growth in the incidence of respiratory infections, particularly in elderly and immunocompromised populations. Additionally, the rise in healthcare expenditure, the presence of advanced healthcare infrastructure, and the availability of reimbursements are anticipated to create lucrative opportunities in the industry. Numerous treatment options such as oseltamivir and acyclovir among others are used to treat the antiviral infection. Likewise, the drugs help reduce the severity of the flu virus spreading into the body, further enhancing the market progression. Thus, more and more consumption of antiviral drugs acts as a major driver of growth in the global pneumonia therapeutics market.

The U.S. Food and Drug Administration approved Xacduro (sulbactam for injection; sulbactam for injection), a new treatment for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible strains of bacteria called Acinetobacter baumannii-calcoaceticus complex, for patients 18 years of age and older.

On World Pneumonia Day, FIRS calls on governments and other stakeholders to take urgent action to tackle pneumonia by:

1. Strengthening health systems capacity.
2. Ensuring that all children and vulnerable adults receive effective pneumonia vaccines.
3. Reducing air pollution and exposure to air pollutants and promoting good nutrition, hygiene practices, and smoking cessation to reduce the risk of pneumonia.
4. Raising awareness and knowledge about pneumonia prevention and treatment.
5. Improving access to antibiotics, pulse oximetry, and oxygen therapy.
6. Encouraging funders to invest in pneumonia research and services and supporting research to implement pneumonia prevention and treatment interventions.To know about the Research Methodology:-Request Free Sample Report

Pneumonia Testing Market Dynamic:

Driving Factors and Growth Opportunities in the Community-Acquired Pneumonia Treatment Market

The rising prevalence of pneumonia and concerns associated with pneumonia mortality are notably driving the market research growth. Driving the demand for pneumonia testing helps in identifying the causative agent of the disease and providing appropriate treatment. The elderly population is more susceptible to pneumonia and other respiratory infections. Many governmental organizations throughout the world are investing in research & development operations to produce new antibiotics, as well as measures to encourage effective community-acquired bacterial pneumonia treatment diagnosis and treatment. The activities and financing are likely to propel the growth of the global community-acquired bacterial pneumonia treatment market.

The burgeoning healthcare industry represents one of the key factors driving the market. There is an increased need for accurate testing procedures because elderly people are more vulnerable to respiratory infections, including pneumonia. Moreover, the demographic factor highlights early detection and the market’s responsibility to meet the unique healthcare needs of the aging population.

The Rise of Point-of-Care Diagnostic Methods

The development of new and more sensitive and specific testing methods is augmenting the global pneumonia testing business. There is a rise in the utilization of point-of-care (POC) testing to detect pneumonia on account of its higher efficiency and rapid and accurate test results. The advanced multiplex PCR (mPCR) based platform for diagnosing pneumonia offers higher detection efficiency, thereby reducing cost and time. The DNA or RNA replication of very minute microorganisms also does not require live microorganisms and is thus not affected by the prior usage of antibiotics.

Therefore with the high prevalence of chronic diseases in a large customer base adopting cost-effective and immediate diagnostic tests, is propelling point-of-care testing. The advantages of the POC test to render rapid and accurate results help in promoting patient-centred healthcare at bedside settings which further results in the adoption of point-of-care testing and thereby promoting the growth of the pneumonia testing market.

Challenges Hindering Growth to Pneumonia Diagnostics Market

The pricing pressure owing to competition and difficulty in diagnosing hamper the growth of the pneumonia diagnostics market through the forecast period. One of the most critical factors restraining the market growth is the widespread utilization of chest X-rays as an essential tool for pneumonia detection.

Similarly, low healthcare awareness across lower economies along with inadequate reimbursement policies is emerging as a significant impediment to the development of the pneumonia diagnostics market. Cultures, the traditional method, are still mostly used to detect pneumonia-causative organisms, which hampers the growth of pneumonia Treatment.

Pneumonia Testing Market Segmentation:

Based on End Users, Pneumonia Testing is mostly used in hospitals and clinics and contributes to the largest market share of 60 %. The rise in adoption of the testing for pneumonia is driving the market growth. Pneumonia is one of the leading causes of mortality and hospitalization among US adults. Hospitalizations for pneumonia have been on the rise, and that trend is particularly true among elderly adults (aged ≥65 years). The elderly are thought to be particularly susceptible to pneumonia requiring hospitalization because of the higher prevalence of comorbid diseases, such as chronic cardiac and pulmonary disease or diabetes mellitus, in that population.  There were around 2,500 hospitals in Colombia, 8240 hospitals in Japan, and 6,120 hospitals in the United States in 2023.

Pneumonia Testing Market Regional Insight:

North America is the largest region with a market share of 38% for the pneumonia testing market owing to the growing burden of pneumonia infection and increasing product approvals. North America has a well-established medical infrastructure, with advanced laboratory facilities and highly trained medical professionals. It also has strong regulatory support for medical technology, including pneumonia testing. Growth in the USA pneumonia diagnostics market is driven by the rising prevalence of pneumonia, increasing diagnostic screening rates owing to high levels of awareness among people, and the presence of leading manufacturers. There has been a significant rise in the cases of pneumonia and pneumonia-related deaths across the USA which has necessitated the adoption of pneumonia diagnostics.

One data source is the National Syndromic Surveillance Program (NSSP), which monitors anonymized daily visit data from around 78% of emergency departments in the United States The diagnosis of pneumonia in children, along with other respiratory illnesses, increases every year during the fall and winter months in the United States. As of November 25, 2023, NSSP data indicated that the weekly percent of emergency department visits with diagnosed pneumonia was

1. 1.7% for children aged 0–1 years,
2. 2.4% for children aged 2–4 years, and
3. 1.5% for children aged 5–17 years.

About 1 million adults in the US seek care in a hospital due to pneumonia every year and 50,000 die from Pneumonia. Then the age extremes, it is always a threat. Half of all non-immunocompromised adults hospitalized for severe pneumonia in the US are younger adults (18-57 years of age).

Competitive Landscape:

In August 2023, Science and medical technology firm Danaher announced that agreed to acquire Abcam, a Cambridge, and U.K.-based supplier of antibodies, reagents, biomarkers, and assays. Under the agreement, Danaher will acquire all outstanding Abcam shares for $24 per share in cash, with a total enterprise value of approximately $5.7 billion, including Abcam's assumed debts and net of acquired cash.
In October 2023, Merk & Co. acquired ImaBIotech. ImaBIotech’s focus is on developing new antibiotics for multi-drug-resistant bacterial infections. The acquisition signifies continued, which is crucial for treating bacterial pneumonia.

Pneumonia Testing Market Scope: Inquire before buying

Pneumonia Testing Market, by Region:-

North America (United States, Canada, and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, and the Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan, and the Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria, and the Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

Key players of the Pneumonia Testing Industry:

1. Thermo Fisher Scientific Inc.
2. Abbott Laboratories
3. F-Hoffmann la Roche Ltd.
4. Hologic Inc.
5. BioMerieux
6. Becton
7. Dickenson and Company
8. Bio-Rad Laboratories Inc.
9. Meridian Biosciences
10. Quest Diagnostics, and Quidel.
11. AdvanDx
12. Beckman Coulter
13. Cepheid
14. Concile
15. Diamedix
16. DiaSorin
17. Fast-track Diagnostics
18. SeraCare
19. Trinity Biotech

Frequently Asked Questions:

1] What segments are covered in the Pneumonia Testing Market report?
Ans. The segments covered in the Pneumonia Testing Market report are based on Type, Methods, and End Users.

2] Which region is expected to hold the highest share in the Pneumonia Testing Market?
Ans. The North American region is expected to hold the highest share of the Pneumonia Testing Market.

3] What is the market size of the Pneumonia Testing Market by 2030?
Ans. The market size of the Pneumonia Testing Market by 2030 will be $ 3.5 Billion.

4] What is the forecast period for the Pneumonia Testing Market?
Ans. The Forecast period for the Pneumonia Testing Market is 2024- 2030.